SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

55 4Q 2017 1Q 2018 2Q 2018 3Q 2018 LTM (1) Sales Treximet $18 $14 $5 $6 $42 Zohydro ER 6 7 8 7 28 Silenor 7 5 6 6 24 Other 11 2 2 3 17 Total Net Sales $42 $28 $21 $21 $112 COGS (14) (9) (6) (6) (35) Operating Expenses (53) (28) (20) (17) (118) EBIT ($25) ($9) ($4) ($2) ($40) Adjusted EBITDA $12 $3 ($0) ($0) $15 Non - GAAP Detailed 2018 Quarterly Results ( 2 ) Non - GAAP 2018 Quarterly Results • Revenue declines predominately attributable to Treximet ® LOE in February 2018 • Generic / Other revenue declined on account of the withdrawal of IDA and desvenlafaxine, which collectively accounted for $18.2M of revenue in 2017 • Operating expenses reduced in order to right - size the Company’s cost structure $42 $28 $21 $21 $12 $3 ($0) ($5) $5 $15 $25 $35 $45 4Q 2017 1Q 2018 2Q 2018 3Q 2018 Total Net Sales Adjusted EBITDA ($0) ($ in millions) 1) LTM as of 9/30/2018. 2) Excludes impact of Contrave ® . LTM (1) Quarterly Results A B C A B C